12th Feb 2021 16:26
GlaxoSmithKline plc (the 'Company')
2021 Awards under the Deferred Investment Award Programme
Notional Award
On 10 February 2021, the Company granted awards over notional Ordinary Shares to Persons Discharging Managerial Responsibilities ('PDMRs') under the GlaxoSmithKline Deferred Investment Award programme.
Under the programme, awards are made over notional Ordinary Shares with vesting phased over a specified period to provide long-term alignment with shareholders. Vesting is subject to the PDMR not having served the Company notice or having been terminated by the Company for cause. Dividends will accrue on the award during the vesting period through reinvestment in additional notional shares. On vesting, the award and accrued dividends will be paid in cash. Executive Directors are not eligible to receive awards under the programme.
The awards have been made to support the retention of the PDMRs listed below. The awards will vest 50% on 10 February 2024, 25% on 10 February 2025, and the balance on 10 February 2026.
The closing Ordinary Share price on 10 February 2021, used to determine the awards, was £12.75.
Transaction notification
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr R Connor | |||
b) | Position/status | President, Global Vaccines | |||
c) | Initial notification/ amendment | Initial Notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
| |||
b) | Nature of the transaction | A restricted award of notional Ordinary Shares under the Company's Deferred Investment Award programme.
| |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£12.75 | 78,431.373 | ||||
d) | Aggregated information | n/a (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2021-02-10 | |||
f) | Place of the transaction
| n/a | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr L Miels | |||
b) | Position/status | President, Global Pharmaceuticals | |||
c) | Initial notification/ amendment | Initial Notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
| |||
b) | Nature of the transaction | A restricted award of notional Ordinary Shares under the Company's Deferred Investment Award programme.
| |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£12.75 | 78,431.373 | ||||
d) | Aggregated information | n/a (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2021-02-10 | |||
f) | Place of the transaction
| n/a | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr R Simard | |||
b) | Position/status | President, Pharmaceuticals Supply Chain | |||
c) | Initial notification/ amendment | Initial Notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
| |||
b) | Nature of the transaction | A restricted award of notional Ordinary Shares under the Company's Deferred Investment Award programme.
| |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£12.75 | 39,215.686 | ||||
d) | Aggregated information | n/a (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2021-02-10 | |||
f) | Place of the transaction
| n/a | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Ms D Waterhouse | |||
b) | Position/status | CEO of ViiV Healthcare | |||
c) | Initial notification/ amendment | Initial Notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
| |||
b) | Nature of the transaction | A restricted award of notional Ordinary Shares under the Company's Deferred Investment Award programme.
| |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£12.75 | 78,431.373 | ||||
d) | Aggregated information | n/a (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2021-02-10 | |||
f) | Place of the transaction
| n/a | |||
Related Shares:
Glaxosmithkline